|Hospital:||University of Minnesota Medical School|
|Patients: This Phase II study involved 15 patients with mesothelioma.|
Treatment: The treatment consisted of the administration of the drug, doxorubicin (doxil).
Toxicity: Toxicities included neutrophils (grade 3 and 4), skin (grade 1 and 2), mucositis (grade 1 and 2), nausea (grade 1), and fatigue (grade 1).
Results: One patient had a partial response. Overall survival was not discussed.